EU Clears Wegovy Weight-Loss Tablet

For millions of Europeans living with obesity, the needle was the line they would not cross. Semaglutide, the drug behind Wegovy and Ozempic, has moved obesity treatment from the margins of medicine into the ordinary conversation of clinics, pharmacies and kitchen tables. But the weekly injection remained a practical and psychological barrier. The European Commission has now authorised a daily Wegovy pill, approved for adults with obesity, or those who are overweight and have at least one related health condition.

At first glance, a tablet feels like the obvious answer. The biology is less straightforward.

Getting a Protein Past Your Stomach

Semaglutide works by copying GLP-1, a gut hormone released after eating. It strengthens the body's own fullness signals, slows digestion and, over time, reduces appetite. This is not a fat burner in the old diet-pill sense. It is closer to a dial on satiety. In a peer-reviewed trial published in The Lancet, oral semaglutide led to an average 15.1% loss of body weight after 68 weeks, compared with 2.4% on placebo.

The difficulty is that semaglutide is a peptide, a protein-like chain, and the stomach is designed to break such material down. Acid and enzymes usually destroy peptides before they can enter the bloodstream, which is why GLP-1 medicines first came as injections. The tablet relies on a compound called SNAC, which forms a short-lived protective shield around the drug, allowing a small amount to pass through the stomach lining. It works, but only under tight conditions. The pill must be taken first thing in the morning on an empty stomach, with a small sip of water, followed by at least 30 minutes without food, drink or other medicines.

That is a real bargain, and not an entirely easy one. A weekly injection is unpleasant but occasional. A daily tablet removes the needle but adds a morning routine that can be thrown off by coffee, breakfast, shift work or simple forgetfulness. The side effects, mainly nausea and digestive discomfort, are broadly similar however the drug gets into the body. This is a new route into treatment, but not automatically a simpler one.

27 Countries, 27 Price Tags

EU authorisation allows the pill to be sold. It does not mean public health systems will pay for it. Each member state decides separately whether to reimburse the medicine, who qualifies, and at what price. There will be no single European Wegovy market in practice, only 27 national arguments about access.

France began reimbursing the injectable version at 65% in mid-June 2026, but only for severe obesity, after documented failure of diet-based treatment, and only when treatment is started by a specialist. The oral pill does not yet have a French price listing.

Germany may prove harder terrain. Weight-management medicines can be classed as lifestyle products and excluded from statutory insurance, even where obesity brings serious medical risks. Sweden has gone further. Its national pricing authority refused to include Wegovy in its subsidy scheme in February 2026, saying Novo Nordisk had not shown reasonable cost. Strong trial results did not settle the question.

Denmark, unsurprisingly, marked the approval as a milestone for one of its great pharmaceutical companies. Independent analysis suggests the tablet also gives Novo Nordisk an early advantage over Eli Lilly, whose rival oral products are not expected until around 2027.

What Comes After the First Pill

That rivalry may shape the market more than this approval alone. Lilly's oral candidate, orforglipron, is built differently: a small synthetic molecule rather than a protein-like chain. Because it does not need the same protective trick to survive the stomach, analysts expect it could be cheaper to manufacture and free from the strict fasting rules that make semaglutide tablets demanding. The contest will come down to convenience, production cost and whether health systems are willing to reimburse.

There is a wider caution too. A review highlighted by Science Media Centre España warned that decisions on obesity medicines should consider quality of life, safety and treatment burden, not only kilograms lost. GLP-1 medicines also sit on an uneasy line between treating a chronic disease and feeding consumer demand for thinness, a tension German and Dutch health authorities are already managing.

The Wegovy tablet is real progress: a powerful class of medicines has become available to people who would never accept an injection. But for most Europeans, the decisive approval will not be in Brussels. It will happen country by country, at the reimbursement desk.